Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 10/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303492 | 0.85 | MAP3K5 (0.55) | MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1303978 | 0.81 | MAP3K5 (0.58) | MAP3K5PIK3CAPIK3CG | |
| SCHEMBL14318039 | 0.81 | MAP3K5 (0.62) | MAP3K5PIK3CGROCK2NPC1RAB9A | |
| SCHEMBL1302695 | 0.77 | MAP3K5 (0.46) | MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL19428335 | 0.75 | FPR2 (0.52) | NPC1RAB9AFPR3FPR2 | |
| SCHEMBL3716984 | 0.75 | MAP3K5 (0.51) | MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL3709433 | 0.75 | MAP3K5 (0.53) | MAP3K5ROCK2NPC1RAB9A | |
| SCHEMBL1303590 | 0.74 | MAP3K5 (0.47) | MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1303903 | 0.73 | MAP3K5 (0.46) | MAP3K5PIK3CAPIK3CGROCK2NPC1 | |
| SCHEMBL31204267 | 0.73 | MAP3K5 (0.50) | MAP3K5PIK3CGROCK2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | MAP3K5 160/4885PIK3CA 1/4885PIK3CG 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.